Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14014603 | 0.92 | HSD17B10 (0.46) | HSD17B10EGLN1DHODHKEAP1NFE2L2 | |
| SCHEMBL4708884 | 0.89 | CSNK1D (0.49) | HSD17B10ALDH1A1KDM4EAXLFLT3 | |
| SCHEMBL14014496 | 0.89 | KDM4E (0.56) | HSD17B10EGLN1KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL14014888 | 0.88 | CAMKK2 (0.47) | KEAP1NFE2L2ALDH1A1KDM4EAXL | |
| SCHEMBL14014543 | 0.88 | ALKBH1 (0.46) | HSD17B10EGLN1KEAP1NFE2L2AXL | |
| SCHEMBL14014911 | 0.87 | CAMKK1 (0.44) | EGLN1KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL4708828 | 0.86 | CAMKK2 (0.44) | DHODHKEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL14014598 | 0.86 | HSD17B10 (0.41) | HSD17B10KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL14014880 | 0.86 | KEAP1 (0.46) | KEAP1NFE2L2ALDH1A1KDM4EAXL | |
| SCHEMBL14014902 | 0.85 | KEAP1 (0.43) | KEAP1NFE2L2FLT3PIM1CAMKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1934225-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1511751-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | Neogenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | HSD17B10 3322/4885EGLN1 2263/4885DHODH 120/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | HSD17B10 4380/4885EGLN1 3789/4885DHODH 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.